MCID: GST040
MIFTS: 67

Gastric Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gastric Adenocarcinoma

MalaCards integrated aliases for Gastric Adenocarcinoma:

Name: Gastric Adenocarcinoma 12 15 17 71
Adenocarcinoma of Stomach 12 6
Stomach Adenocarcinoma 12
Adenocarcinoma Gastric 54

Classifications:



External Ids:

Disease Ontology 12 DOID:3717
NCIt 50 C4004
SNOMED-CT 67 408647009
UMLS 71 C0278701

Summaries for Gastric Adenocarcinoma

Disease Ontology : 12 A stomach carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Gastric Adenocarcinoma, also known as adenocarcinoma of stomach, is related to gastric papillary adenocarcinoma and gastric cancer, hereditary diffuse, and has symptoms including dyspepsia An important gene associated with Gastric Adenocarcinoma is HOTAIR (HOX Transcript Antisense RNA), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Rabeprazole and Proton Pump Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include lymph node, endothelial and bone marrow, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Stomach cancer, also known as gastric cancer, is a cancer that develops from the lining of the stomach.... more...

Related Diseases for Gastric Adenocarcinoma

Diseases related to Gastric Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 713)
# Related Disease Score Top Affiliating Genes
1 gastric papillary adenocarcinoma 32.6 TP53 ERBB2
2 gastric cancer, hereditary diffuse 32.5 TP53 SMAD4 PTEN MLH1 KRAS CTNNB1
3 adenocarcinoma 31.6 TP53 SMAD4 PTEN PIK3CA MLH1 KRAS
4 microinvasive gastric cancer 31.6 TP53 MLH1 ERBB2
5 signet ring cell adenocarcinoma 31.3 TP53 MLH1 KRAS HRAS ERBB2 CTNNB1
6 gastrointestinal stromal tumor 31.1 TP53 PTEN KRAS HOTAIR ERBB2 CDKN2A
7 adenoma 31.0 TP53 SMAD4 PIK3CA MLH1 KRAS CTNNB1
8 barrett esophagus 31.0 TP53 SMAD4 ERBB2 CTNNB1 CDKN2A
9 papilloma 31.0 TP53 PTEN KRAS ERBB2 CDKN2A AKT1
10 familial adenomatous polyposis 30.9 TP53 SMAD4 MLH1 KRAS HRAS CTNNB1
11 mucinous adenocarcinoma 30.9 TP53 MLH1 KRAS ERBB2 CDKN2A
12 peutz-jeghers syndrome 30.9 TP53 SMAD4 PTEN CTNNB1
13 diffuse large b-cell lymphoma 30.8 TP53 PTEN HOTAIR CDKN2A AKT1
14 barrett's adenocarcinoma 30.8 TP53 KRAS ERBB2 CDKN2A
15 appendix adenocarcinoma 30.8 KRAS HRAS
16 keratosis 30.7 TP53 PIK3CA HRAS CDKN2A
17 peripheral nervous system disease 30.7 TP53 PTEN HRAS ERBB2 CTNNB1 CDKN2A
18 neurofibroma 30.7 TP53 PTEN ERBB2 CDKN2A
19 epstein-barr virus-associated gastric carcinoma 30.6 PIK3CA CTNNB1 CDKN2A
20 intrahepatic cholangiocarcinoma 30.6 TP53 SMAD4 KRAS FGFR2 ERBB2 CTNNB1
21 squamous cell carcinoma 30.6 TP53 SMAD4 PTEN PIK3CA NEAT1 HRAS
22 colorectal adenocarcinoma 30.5 TP53 PTEN MLH1 KRAS HRAS ERBB2
23 small cell carcinoma 30.5 TP53 PTEN KRAS ERBB2 CDKN2A
24 esophageal cancer 30.4 TP53 SMAD4 PTEN PIK3CA MLH1 KRAS
25 histiocytic sarcoma 30.4 PTEN CDKN2A
26 squamous cell papilloma 30.4 TP53 HRAS CDKN2A
27 gallbladder adenocarcinoma 30.4 TP53 PIK3CA ERBB2
28 breast adenocarcinoma 30.4 TP53 PIK3CA KRAS H19 ERBB2 AKT1
29 adenomyoma 30.4 MLH1 CTNNB1 CDKN2A
30 mucoepidermoid carcinoma 30.4 TP53 ERBB2 CTNNB1 CDKN2A
31 thyroid carcinoma 30.4 PTEN PIK3CA NEAT1 HOTAIR H19
32 pseudomyxoma peritonei 30.4 TP53 KRAS CTNNB1
33 glioma 30.4 TP53 PTEN PIK3CA NEAT1 HOTAIR H19
34 kidney cancer 30.4 TP53 PTEN PIK3CA HOTAIR H19 CDKN2A
35 chordoma 30.4 TP53 PTEN CDKN2A AKT1
36 tuberous sclerosis 30.4 TP53 PTEN PIK3CA AKT1
37 breast ductal carcinoma 30.3 TP53 SMAD4 ERBB2 CTNNB1
38 adrenal cortical carcinoma 30.3 TP53 PIK3CA H19 CTNNB1
39 cervical adenocarcinoma 30.3 TP53 PTEN KRAS ERBB2 CDKN2A AKT1
40 lynch syndrome 30.3 TP53 SMAD4 PTEN PIK3CA MLH1 KRAS
41 exanthem 30.3 KRAS HRAS ERBB2 AKT1
42 hepatoblastoma 30.3 TP53 H19 CTNNB1 AKT1
43 hemangioma 30.3 TP53 PTEN KRAS CTNNB1 AKT1
44 villous adenoma 30.2 TP53 MLH1 KRAS HRAS
45 renal cell carcinoma, nonpapillary 30.2 TP53 PTEN PIK3CA HRAS HOTAIR H19
46 myeloma, multiple 30.2 TP53 PTEN PIK3CA KRAS HRAS HOTAIR
47 small cell cancer of the lung 30.2 TP53 PTEN PIK3CA HOTAIR CDKN2A AKT1
48 basal cell carcinoma 30.2 TP53 PTEN MLH1 CTNNB1 CDKN2A
49 pancreatic adenocarcinoma 30.2 TP53 SMAD4 PIK3CA KRAS HRAS ERBB2
50 duodenum disease 30.2 TP53 SMAD4 MLH1 KRAS HRAS

Graphical network of the top 20 diseases related to Gastric Adenocarcinoma:



Diseases related to Gastric Adenocarcinoma

Symptoms & Phenotypes for Gastric Adenocarcinoma

UMLS symptoms related to Gastric Adenocarcinoma:


dyspepsia

GenomeRNAi Phenotypes related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.09 HRAS KRAS PIK3CA
2 Decreased viability GR00055-A-2 10.09 HRAS KRAS PIK3CA
3 Decreased viability GR00055-A-3 10.09 KRAS
4 Decreased viability GR00106-A-0 10.09 KRAS
5 Decreased viability GR00221-A-1 10.09 AKT1 CDKN2A HRAS KRAS PIK3CA
6 Decreased viability GR00221-A-2 10.09 AKT1 HRAS KRAS PIK3CA
7 Decreased viability GR00221-A-3 10.09 AKT1 CDKN2A HRAS
8 Decreased viability GR00221-A-4 10.09 AKT1 CDKN2A PIK3CA
9 Decreased viability GR00249-S 10.09 AKT1
10 Decreased viability GR00301-A 10.09 KRAS
11 Decreased viability GR00381-A-1 10.09 KRAS
12 Decreased viability GR00402-S-2 10.09 PIK3CA
13 Decreased cell migration GR00055-A-1 9.43 AKT1
14 Decreased cell migration GR00055-A-3 9.43 HRAS PIK3CA
15 Decreased sensitivity to paclitaxel GR00112-A-0 8.85 PTEN
16 Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading GR00210-A 8.32 CTNNB1

MGI Mouse Phenotypes related to Gastric Adenocarcinoma:

46 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.29 AKT1 CDKN2A CTNNB1 ERBB2 FGFR2 HRAS
2 endocrine/exocrine gland MP:0005379 10.29 AKT1 CDKN2A CTNNB1 ERBB2 FGFR2 HRAS
3 integument MP:0010771 10.27 AKT1 CDKN2A CTNNB1 ERBB2 FGFR2 HRAS
4 digestive/alimentary MP:0005381 10.24 CDKN2A CTNNB1 ERBB2 FGFR2 HRAS KRAS
5 embryo MP:0005380 10.22 AKT1 CDKN2A CTNNB1 ERBB2 FGFR2 KRAS
6 neoplasm MP:0002006 10.18 AKT1 CDKN2A CTNNB1 ERBB2 FGFR2 HRAS
7 muscle MP:0005369 10.17 AKT1 CDKN2A CTNNB1 ERBB2 FGFR2 HRAS
8 liver/biliary system MP:0005370 10.06 AKT1 CDKN2A CTNNB1 FGFR2 KRAS PTEN
9 limbs/digits/tail MP:0005371 10.02 CTNNB1 ERBB2 FGFR2 KRAS PTEN SMAD4
10 normal MP:0002873 9.97 AKT1 CTNNB1 ERBB2 FGFR2 HRAS KRAS
11 no phenotypic analysis MP:0003012 9.91 CDKN2A CTNNB1 FGFR2 HRAS KRAS PIK3CA
12 reproductive system MP:0005389 9.9 AKT1 CDKN2A CTNNB1 ERBB2 FGFR2 KRAS
13 pigmentation MP:0001186 9.73 CDKN2A CTNNB1 FGFR2 KRAS PTEN TP53
14 respiratory system MP:0005388 9.65 AKT1 CDKN2A CTNNB1 ERBB2 FGFR2 HRAS
15 skeleton MP:0005390 9.36 AKT1 CDKN2A CTNNB1 ERBB2 FGFR2 HRAS

Drugs & Therapeutics for Gastric Adenocarcinoma

Drugs for Gastric Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 144)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
2 Proton Pump Inhibitors Phase 4
3
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
4
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
5
Floxuridine Approved Phase 3 50-91-9 5790
6
Midazolam Approved, Illicit Phase 3 59467-70-8 4192
7
Pancrelipase Approved, Investigational Phase 3 53608-75-6
8
Trastuzumab Approved, Investigational Phase 2, Phase 3 180288-69-1 9903
9
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 6857599 43805
10
Fluorouracil Approved Phase 3 51-21-8 3385
11
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
12
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
13
Epirubicin Approved Phase 3 56420-45-2 41867
14
Racepinephrine Approved Phase 3 329-65-7 838
15
Epinephrine Approved, Vet_approved Phase 3 51-43-4 5816
16
Doxifluridine Investigational Phase 3 3094-09-5
17 Liver Extracts Phase 3
18 Central Nervous System Stimulants Phase 3
19 pancreatin Phase 3
20 Hematinics Phase 3
21 Antimetabolites Phase 3
22 Immunologic Factors Phase 3
23 Immunosuppressive Agents Phase 3
24 Epinephryl borate Phase 3
25
Lenograstim Approved, Investigational Phase 2 135968-09-1
26
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
27
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
28
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
29
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
30
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
31
Olaparib Approved Phase 2 763113-22-0 23725625
32
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
33
Linagliptin Approved Phase 1, Phase 2 668270-12-0 10096344
34
Niraparib Approved, Investigational Phase 2 1038915-60-4 24958200
35
Ipilimumab Approved Phase 2 477202-00-9
36
Durvalumab Approved, Investigational Phase 2 1428935-60-7
37
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
38
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
39
ramucirumab Approved, Investigational Phase 2 947687-13-0
40
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
41
nivolumab Approved Phase 2 946414-94-4
42
Bevacizumab Approved, Investigational Phase 2 216974-75-3
43
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
44
leucovorin Approved Phase 2 58-05-9 6006
45
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
46
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
47
Pembrolizumab Approved Phase 2 1374853-91-4
48
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
49
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
50
Nimotuzumab Investigational Phase 2 780758-10-3, 828933-61-3

Interventional clinical trials:

(show top 50) (show all 206)
# Name Status NCT ID Phase Drugs
1 An Open Label, Single Group Assigned, Multicenter Study of Apatinib in Patients With Chemo-refractory Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction Unknown status NCT02426034 Phase 4 Apatinib
2 Effects of Preoperative Administration of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection(EMR): Prospective, Randomized, Placebo-controlled, Comparative Study Completed NCT00844675 Phase 4 rabeprazole;placebo
3 A Randomized, Multicenter, Open-label, Phase III Trial of Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected (D2) Gastric Cancer of Stage IIIB/IV (M0) Unknown status NCT01283217 Phase 3 DS;SP
4 A Phase III Study of Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2 Lymphadenectomy Unknown status NCT02240524 Phase 3
5 Phase III, Randomized, Multicenter, Controlled Evaluation of S-1 and Oxaliplatin as Neoadjuvant Chemotherapy for Advanced Gastric Cancer Patients Unknown status NCT01583361 Phase 3 Oxaliplatin+S-1;Adjuvant Oxaliplatin/S-1(SOX)
6 Randomized Phase 3 Study of Xelox(Capecitabine Plus Oxaliplatin) Followed by Maintenance Capecitabine or Observation in Patients With Advanced Gastric Adenocarcinoma Unknown status NCT02289547 Phase 3 Capecitabine
7 Phase Ⅱ/Ⅲ Study of Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma Unknown status NCT02193594 Phase 2, Phase 3 Adjuvant chemotherapy
8 Phase III Randomized Trial of Adjuvant XELOX Chemotherapy and XELOX With Concurrent Capecitabine and Radiotherapy for Gastric Adenocarcinoma With D2 Dissection Unknown status NCT01711242 Phase 3 Capecitabine;Oxaliplatin
9 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT02545504 Phase 3 Andecaliximab;Placebo;Leucovorin;5-fluorouracil;Oxaliplatin
10 Comparison of Efficacy of Covered Versus Uncovered Self-expandable Metallic Stents for Treatment of Malignant Gastric Outlet Obstruction: a Prospective, Randomized Study Completed NCT01646476 Phase 3
11 A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL) Completed NCT02314117 Phase 3 Ramucirumab;Capecitabine;Cisplatin;Placebo;Fluorouracil
12 A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin vs Surgery Alone in Patients With Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4NO), and IIIb (T3N2) Gastric Adenocarcinoma Completed NCT00411229 Phase 3 Capecitabine;Oxaliplatin
13 A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine Completed NCT01170663 Phase 3 Placebo;Paclitaxel
14 A Randomized, Open, Multi-center, Phase III Study of S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment in Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma Patients Completed NCT01824459 Phase 3 S-1;Oxaliplatin;Cisplatin
15 A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin Versus Surgery Alone in Patients With Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4N0) and IIIb (T3N2) Gastric Adenocarcinoma Completed NCT02560974 Phase 3 Capecitabine;Oxaliplatin
16 A Phase III Randomized Controlled Trial of Adjuvant Chemotherapy for Advanced Gastric Adenocarcinoma Completed NCT00296335 Phase 3 Mitomycin, doxifluridine and cisplatin;Mitomycin and doxifluridine
17 A Phase III Randomized Controlled Trial of Adjuvant Chemotherapy for Gastric Adenocarcinoma: Mitomycin and Doxifluridine Versus Intraperitoneal Chemotherapy and Mitomycin, Doxifluridine, and Cisplatin Completed NCT00296322 Phase 3 cisplatin, mitomycin-C, doxifluridine
18 Phase III Randomized Controlled Trial of Adjuvant Capecitabine/Cisplatin Chemotherapy and Chemoradiation Therapy for Gastric Adenocarcinoma Completed NCT00323830 Phase 3 Capecitabine, cisplatin, Radiotherapy (+/-)
19 Open-label, Randomized, Controlled, Multicenter Phase III Study Investigating Cetuximab in Combination With Capecitabine (Xeloda, X) and Cisplatin (P) Versus XP Alone as First-line Treatment for Subjects With Advanced Gastric Adenocarcinoma Including Adenocarcinoma of the Gastroesophageal Junction Completed NCT00678535 Phase 3 Cetuximab;Capecitabine;Cisplatin
20 Randomised Phase III Study of Docetaxel vs Active Symptom Control in Patients With Relapsed Oesophago-gastric Adenocarcinoma Completed NCT00978549 Phase 3 docetaxel;steroid therapy
21 A Phase III Trial of Preoperative or Postoperative Chemoradiation Therapy for Potentially Resectable Adenocarcinoma of Stomach Cancer Recruiting NCT03223740 Phase 3
22 Neoadjuvant S1, Oxaliplatin, and Docetaxel (SLOT) Versus S1, Oxaliplatin(SOX) in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer Recruiting NCT02512380 Phase 3 Docetaxel;oxaliplatin;s1;oxaliplatin;s1
23 GASTRICHIP : D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma. A Randomized and Multicentric Phase III Study. Recruiting NCT01882933 Phase 3 HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin
24 A Multicenter Randomized Clinical Trial of D1+ Versus D2 Distal Gastrectomy for Stage IB & II Advanced Gastric Cancer Recruiting NCT02144727 Phase 3
25 A Multi-Center, Double-Blind, Randomized, Phase III Study of CS1001 in Combination With XELOX Chemotherapy Compared to Placebo in Combination With XELOX Chemotherapy in Subjects With Unresectable Locally Advanced or Metastatic GC or GEJ Adenocarcinoma Recruiting NCT03802591 Phase 3 CS1001 monoclonal antibody;CS1001 placebo;Oxaliplatin;Capecitabine
26 Phase III, Randomized, Open-label Study of Adjuvant Chemotherapy Combined With Chemoradiotherapy Versus Adujvant Chemotherapy After Standard D2 Resection for Locally Advanced Proximal Gastric Adenocarcinoma Recruiting NCT03973008 Phase 3 Adjuvant Chemotherapy
27 A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC) Recruiting NCT04499924 Phase 2, Phase 3 tucatinib;trastuzumab;ramucirumab;paclitaxel
28 A Multi-center, Open-label, Randomized Controlled Study of Albumin-bound Paclitaxel Plus S-1 Versus Oxaliplatin Plus S-1 (SOX) as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma Recruiting NCT03801668 Phase 3 Albumin-bound Paclitaxel plus S-1;Oxaliplatin plus S-1
29 A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA) Recruiting NCT04248452 Phase 3 Capecitabine;Fluorouracil;Leucovorin;Leucovorin Calcium;Oxaliplatin
30 An Randomized, Multicenter, Open-label, Phase III Trial Comparing Neoadjuvant Chemoradiotherapy Versus Chemotherapy in Patients With Locally Advanced Gastric Adenocarcinoma Recruiting NCT01815853 Phase 3 Neoadjuvant Chemotherapy;Adjuvant Chemotherapy
31 Capecitabine or Observation for Patients With pT1N+M0 or pT2-3N0M0 Gastric Adenocarcinoma Undergoing R0 Resection (CAPOGA): A Large Multicenter Phase III Randomized Controlled Trial Recruiting NCT03817268 Phase 3 Capecitabine monotherapy
32 A Randomized, Multicenter, Controlled, Adaptive II/III Study to Compare Neoadjuvant Chemotherapy of Docetaxel,Oxaliplatin Combined With S-1(DOS) Versus Oxaliplatin Combined With S-1(SOX)in Locally Advanced Gastric Adenocarcinoma (RESOLVE-2 Study) Active, not recruiting NCT03691454 Phase 2, Phase 3 Docetaxel;Oxaliplatin
33 A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine Active, not recruiting NCT02370498 Phase 3 paclitaxel
34 A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil Versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects With Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Active, not recruiting NCT02494583 Phase 3 Cisplatin;5-FU;Capecitabine;Placebo
35 Phase III Randomized Trial of Adjuvant Chemotherapy With S-1 vs S-1/Oxaliplatin ± Radiotherapy for Completely Resected Gastric Adenocarcinoma : The ARTIST II Trial Active, not recruiting NCT01761461 Phase 3 TS-1, oxaliplatin
36 A Randomized, Multicenter, Controlled Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection Active, not recruiting NCT01534546 Phase 3 Oxaliplatin capecitabine;Oxaliplatin S-1;Oxaliplatin S-1
37 A Randomized, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Sintilimab Combined With Ramucirumab as Compared to Chemotherapy for the First-line Treatment of Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (ORIENT-106) Not yet recruiting NCT04675983 Phase 3 Sintilimab;Ramucirumab;Cisplatin;5-fluorouracil;Oxaliplatin;Capecitabine
38 Palliative Gastric Resection Plus Chemotherapy Versus Chemotherapy Alone in Stage IV Gastric Cancer - a Multicenter Prospective Open-labeled, Two-armed, Randomized Controlled Phase III Trial Not yet recruiting NCT03042169 Phase 3 Preoperative Chemotherapy;Postoperative chemotherapy
39 The Efficacy and Safety of Postoperative Chemotherapy With Docetaxel Plus Oxaliplatin and Capecitabine Versus Oxaliplatin Plus Capecitabine for Postoperative Pathological Stage IIIB/IIIC Gastric Adenocarcinoma: a Randomised, Phase 3 Trial Not yet recruiting NCT04351867 Phase 3 docetaxel plus oxaliplatin and capecitabine;oxaliplatin plus capecitabine
40 ITACA-S2(Intergroup Trial in Adjuvant Chemotherapy for Adenocarcinoma of the Stomach:Comparison of the Efficacy of a Peri-operative Versus a Post-operative Chemotherapy Treatment in Patients With Operable Gastric Cancer and Assessment of the Benefit of a Post-operative Chemo-radiotherapy. Terminated NCT01989858 Phase 3
41 A Randomized Phase II Multicenter Controlled Study of Oxaliplatin, Calcium Folinate, and 5-Fluorouracil as Neoadjuvant Chemotherapy for Resectable Advanced Gastric Cancer Unknown status NCT00591045 Phase 2 mFOLFOX
42 Multi-center Phase II Trial of Nimotuzumab Plus Irinotecan in Patients With High EGFR Expression After Failure of First-line Treatment in Recurrent or Metastatic Gastric Adenocarcinoma(NIEGA) Unknown status NCT03400592 Phase 2 Irinotecan;nimotuzumab
43 A Randomized Single Center Phase II Study Comparing XELOX With Capecitabine Maintenance or XELOX Treatment in Elderly Metastatic Adenocarcinoma of Stomach Unknown status NCT01798251 Phase 2 Oxaliplatin;Capecitabine
44 A Phase II Trial to Assess the Efficacy and Safety of Panitumumab Combined With Docetaxel and Cisplatin as a First-line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Unknown status NCT01379807 Phase 2 panitumumab + docetaxel + cisplatino
45 A Multicenter, Single Arm, Open-label Trial of Oxaliplatin Plus Capecitabine (XELOX) in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma Unknown status NCT01880632 Phase 2 XELOX
46 A Phase II Trial Evaluate a Modified SOX Regimen in First-Line Treatment of Unresectable Gastric Adenocarcinoma Unknown status NCT01552980 Phase 2 S-1 and Oxaliplatin
47 To Evaluate the Efficacy and Safety of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients:a Phase II Single Center Prospective Clinical Trial Unknown status NCT01641783 Phase 2 nanoparticle Albumin-Bound paclitaxel
48 Phase II Study on the Second-line Treatment of Gastric Adenocarcinoma With Apatinib Combined With POF(Paclitaxel Plus Oxaliplatin Plus 5-fluorouracil Plus Leucovorin) Unknown status NCT03788174 Phase 2 Apatinib;POF
49 Phase II Study of the Combination of Apatinib and POF (Paclitaxel Plus Oxaliplatin Plus 5-fluorouracil Plus Leucovorin) Unknown status NCT03707639 Phase 2 Apatinib;POF
50 Phase II Multicenter Study in the Preoperative Treatment of Gastric Adenocarcinoma Consisting of Chemotherapy Using Docetaxel-cisplatin-5FU + Lenograstim Followed by Chemoradiation Based 5FU and Oxaliplatin Unknown status NCT01565109 Phase 2 Docetaxel - Cisplatine - 5FU

Search NIH Clinical Center for Gastric Adenocarcinoma

Genetic Tests for Gastric Adenocarcinoma

Anatomical Context for Gastric Adenocarcinoma

MalaCards organs/tissues related to Gastric Adenocarcinoma:

40
Lymph Node, Endothelial, Bone Marrow, Colon, T Cells, Prostate, Neutrophil

Publications for Gastric Adenocarcinoma

Articles related to Gastric Adenocarcinoma:

(show top 50) (show all 7178)
# Title Authors PMID Year
1
The relationship between Helicobacter pylori infection and gastric adenocarcinoma in Northern Iran. 61 54
20377133 2010
2
CDX2 expression in the intestinal-type gastric epithelial neoplasia: frequency and significance. 54 61
19820687 2010
3
No association of vascular endothelial growth factor-A (VEGF-A) and VEGF-C expression with survival in patients with gastric cancer. 54 61
20057967 2009
4
AFP-producing hepatoid adenocarcinoma of the stomach: a case report. 54 61
20062620 2009
5
Expression of p-Akt and COX-2 in gastric adenocarcinomas and adenovirus mediated Akt1 and COX-2 ShRNA suppresses SGC-7901 gastric adenocarcinoma and U251 glioma cell growth in vitro and in vivo. 61 54
19925030 2009
6
Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions. 54 61
19695681 2009
7
Sanguinarine sensitizes human gastric adenocarcinoma AGS cells to TRAIL-mediated apoptosis via down-regulation of AKT and activation of caspase-3. 61 54
20032392 2009
8
Modification of alternative splicing of Mcl-1 pre-mRNA using antisense morpholino oligonucleotides induces apoptosis in basal cell carcinoma cells. 61 54
19369967 2009
9
Cutoff value of carcinoembryonic antigen and carbohydrate antigen 19-9 elevation levels for monitoring recurrence in patients with resectable gastric adenocarcinoma. 61 54
20082274 2009
10
Inhibitory effects of adenovirus mediated COX-2, Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo. 61 54
19639178 2009
11
[Construction of recombinant adenovirus vector expressing shRNAs targeting COX-2, AKT1 and PIK3R1 gene and its inhibition effect on proliferation of human gastric adenocarcinoma]. 61 54
20017300 2009
12
[Inhibitory effects of targeting protein kinase B1 and cyclooxygenase-2 shRNA upon human gastric adenocarcinoma cell growth]. 61 54
20095346 2009
13
Expression of the antiapoptosis gene Survivin predicts poor prognosis of stage III gastric adenocarcinoma. 54 61
19336448 2009
14
HIF-1alpha determines the metastatic potential of gastric cancer cells. 61 54
19223895 2009
15
Helicobacter pylori cagA status and peptic ulcer disease in Iran. 61 54
18612816 2009
16
EPO-R expression patterns in resected gastric adenocarcinoma followed by adjuvant chemoradiation treatment. 61 54
19002606 2009
17
Osteopontin, CD44, and NFkappaB expression in gastric adenocarcinoma. 61 54
19688069 2009
18
Importance of gastrin in the pathogenesis and treatment of gastric tumors. 54 61
19115463 2009
19
[Protein level of transcription factors AP-1 and NF-kappaB in selected human gastrointestinal tract tumors]. 61 54
19205384 2008
20
[Vasoactive intestinal peptide expression and its clinical significance in gastric adenocarcinoma]. 61 54
19544643 2008
21
Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. 54 61
19061514 2008
22
Disturbed XIAP and XAF1 expression balance is an independent prognostic factor in gastric adenocarcinomas. 54 61
18807090 2008
23
Expression of S100A4, E-cadherin, alpha- and beta-catenin in gastric adenocarcinoma. 61 54
19102422 2008
24
Deregulation of MUC4 in gastric adenocarcinoma: potential pathobiological implication in poorly differentiated non-signet ring cell type gastric cancer. 54 61
18781152 2008
25
Constitutive hypophosphorylation of extracellular signal-regulated kinases-1/2 and down-regulation of c-Jun in human gastric adenocarcinoma. 54 61
18570890 2008
26
Gamma-tocotrienol-induced apoptosis in human gastric cancer SGC-7901 cells is associated with a suppression in mitogen-activated protein kinase signalling. 61 54
18081943 2008
27
Induction of apoptosis by linoleic acid is associated with the modulation of Bcl-2 family and Fas/FasL system and activation of caspases in AGS human gastric adenocarcinoma cells. 54 61
18361731 2008
28
Interrelationship between MYC gene numerical aberrations and protein expression in individuals from northern Brazil with early gastric adenocarcinoma. 61 54
18262050 2008
29
Regulation of mammalian gastrin/CCK receptor (CCK2R) expression in vitro and in vivo. 54 61
17933865 2008
30
The significances of lymph node micrometastasis and its correlation with E-cadherin expression in pT1-T3N0 gastric adenocarcinoma. 54 61
18095267 2008
31
[The effect of siRNA on inhibiting cyclooxygenase-2 gene expression in gastric adenocarcinoma cell]. 54 61
18683800 2008
32
Expression of COX-2 in stomach carcinogenesis. 54 61
19107602 2008
33
Maspin and p53 protein expression in gastric adenocarcinoma and its clinical applications. 61 54
18091326 2008
34
Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma. 61 54
18715846 2008
35
Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy. 61 54
18172256 2008
36
Cysteine-rich 61 (CCN1) enhances chemotactic migration, transendothelial cell migration, and intravasation by concomitantly up-regulating chemokine receptor 1 and 2. 61 54
18025257 2007
37
Genistein sensitizes TRAIL-resistant human gastric adenocarcinoma AGS cells through activation of caspase-3. 54 61
17689858 2007
38
Lysophosphatidic acid inhibits ghrelin secretion in the human gastric adenocarcinoma AGS cell line: role of mitogenic activated protein kinase signaling pathway. 61 54
17937769 2007
39
[Garlic oil inhibits cyclin E expression in gastric adenocarcinoma cells]. 54 61
17715037 2007
40
Correlation between thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level and in vitro chemosensitivity to 5-fluorouracil, in relation to differentiation in gastric cancer. 61 54
17377791 2007
41
Effect of vasoactive intestinal peptide on gastric adenocarcinoma. 61 54
17559364 2007
42
Genetic and epigenetic analysis of the KLF4 gene in gastric cancer. 54 61
17614846 2007
43
Clinicopathologic and prognostic significance of overexpression of her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray. 54 61
19034345 2007
44
Promoter hypermethylation of CDH1, FHIT, MTAP and PLAGL1 in gastric adenocarcinoma in individuals from Northern Brazil. 61 54
17552003 2007
45
Prognostic significance of maspin expression in human gastric adenocarcinoma. 61 54
17591106 2007
46
Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. 61 54
17230506 2007
47
Functional role of beta-adrenergic receptors in the mitogenic action of nicotine on gastric cancer cells. 54 61
17003101 2007
48
[Expression of c-erbB-2 and c-met proteins in gastric adenoma and adenocarcinoma]. 54 61
18172343 2007
49
Clinical significance of tissue levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in gastric cancer. 61 54
17351800 2007
50
Role of proteinase-activated receptor-2 on cyclooxygenase-2 expression in H. pylori-infected gastric epithelial cells. 54 61
17405913 2007

Variations for Gastric Adenocarcinoma

ClinVar genetic disease variations for Gastric Adenocarcinoma:

6 (show top 50) (show all 361)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 POLE NM_006231.3(POLE):c.1231G>T (p.Val411Leu) SNV Likely pathogenic 376503 rs1057519945 12:133250289-133250289 12:132673703-132673703
2 ACVR1 NM_001111067.4(ACVR1):c.773G>T (p.Arg258Met) SNV Likely pathogenic 376364 rs1057519875 2:158626897-158626897 2:157770385-157770385
3 ERBB2 NM_004448.3(ERBB2):c.2329G>T (p.Val777Leu) SNV Likely pathogenic 44991 rs121913471 17:37881000-37881000 17:39724747-39724747
4 ERBB2 NM_004448.3(ERBB2):c.2329G>A (p.Val777Met) SNV Likely pathogenic 376406 rs121913471 17:37881000-37881000 17:39724747-39724747
5 ERBB2 NM_004448.3(ERBB2):c.2264T>G (p.Leu755Trp) SNV Likely pathogenic 376343 rs121913470 17:37880220-37880220 17:39723967-39723967
6 ERBB2 NM_004448.3(ERBB2):c.2264T>C (p.Leu755Ser) SNV Likely pathogenic 376035 rs121913470 17:37880220-37880220 17:39723967-39723967
7 ERBB2 NM_004448.3(ERBB2):c.2033G>A (p.Arg678Gln) SNV Likely pathogenic 376344 rs1057519862 17:37879658-37879658 17:39723405-39723405
8 ERBB2 NM_004448.3(ERBB2):c.2263T>A (p.Leu755Met) SNV Likely pathogenic 376404 rs1057519890 17:37880219-37880219 17:39723966-39723966
9 ERBB3 NM_001982.3(ERBB3):c.889G>T (p.Asp297Tyr) SNV Likely pathogenic 376407 rs1057519891 12:56482341-56482341 12:56088557-56088557
10 ERBB3 NM_001982.3(ERBB3):c.889G>A (p.Asp297Asn) SNV Likely pathogenic 376409 rs1057519891 12:56482341-56482341 12:56088557-56088557
11 ERBB3 NM_001982.3(ERBB3):c.890A>T (p.Asp297Val) SNV Likely pathogenic 376408 rs1057519892 12:56482342-56482342 12:56088558-56088558
12 TP53 NM_000546.5(TP53):c.814G>T (p.Val272Leu) SNV Likely pathogenic 12358 rs121912657 17:7577124-7577124 17:7673806-7673806
13 CTNNB1 NM_001904.4(CTNNB1):c.100G>C (p.Gly34Arg) SNV Likely pathogenic 376233 rs121913399 3:41266103-41266103 3:41224612-41224612
14 TP53 NM_000546.5(TP53):c.451C>A (p.Pro151Thr) SNV Likely pathogenic 12369 rs28934874 17:7578479-7578479 17:7675161-7675161
15 TP53 NM_000546.5(TP53):c.842A>G (p.Asp281Gly) SNV Likely pathogenic 141141 rs587781525 17:7577096-7577096 17:7673778-7673778
16 PPP2R1A NM_014225.6(PPP2R1A):c.547C>T (p.Arg183Trp) SNV Likely pathogenic 376505 rs1057519946 19:52715982-52715982 19:52212729-52212729
17 TP53 NM_000546.5(TP53):c.845G>A (p.Arg282Gln) SNV Likely pathogenic 237956 rs730882008 17:7577093-7577093 17:7673775-7673775
18 RHOA NM_001664.4(RHOA):c.125A>T (p.Tyr42Phe) SNV Likely pathogenic 376524 rs1057519954 3:49412898-49412898 3:49375465-49375465
19 TP53 NM_000546.5(TP53):c.577C>T (p.His193Tyr) SNV Likely pathogenic 230256 rs876658468 17:7578272-7578272 17:7674954-7674954
20 PIK3CA NM_006218.4(PIK3CA):c.1357G>C (p.Glu453Gln) SNV Likely pathogenic 376471 rs1057519925 3:178928079-178928079 3:179210291-179210291
21 TP53 NM_000546.5(TP53):c.809T>C (p.Phe270Ser) SNV Likely pathogenic 376594 rs1057519986 17:7577129-7577129 17:7673811-7673811
22 TP53 NM_000546.5(TP53):c.577C>G (p.His193Asp) SNV Likely pathogenic 376613 rs876658468 17:7578272-7578272 17:7674954-7674954
23 TP53 NM_000546.5(TP53):c.431A>C (p.Gln144Pro) SNV Likely pathogenic 186594 rs786203071 17:7578499-7578499 17:7675181-7675181
24 FGFR1 NM_015850.4(FGFR1):c.1537A>G (p.Met513Val) SNV Likely pathogenic 376430 rs1057519899 8:38275397-38275397 8:38417879-38417879
25 TP53 NM_000546.5(TP53):c.745A>G (p.Arg249Gly) SNV Likely pathogenic 376654 rs587782082 17:7577536-7577536 17:7674218-7674218
26 TP53 NM_000546.5(TP53):c.730G>C (p.Gly244Arg) SNV Likely pathogenic 376602 rs1057519989 17:7577551-7577551 17:7674233-7674233
27 CDKN2A NM_000077.4(CDKN2A):c.239G>A (p.Arg80Gln) SNV Likely pathogenic 376385 rs1057519883 9:21971119-21971119 9:21971120-21971120
28 TP53 NM_000546.5(TP53):c.725G>A (p.Cys242Tyr) SNV Likely pathogenic 12354 rs121912655 17:7577556-7577556 17:7674238-7674238
29 TP53 NM_000546.5(TP53):c.842A>C (p.Asp281Ala) SNV Likely pathogenic 376589 rs587781525 17:7577096-7577096 17:7673778-7673778
30 TP53 NM_000546.5(TP53):c.746G>A (p.Arg249Lys) SNV Likely pathogenic 142241 rs587782329 17:7577535-7577535 17:7674217-7674217
31 TP53 NM_000546.5(TP53):c.815T>G (p.Val272Gly) SNV Likely pathogenic 233323 rs876660333 17:7577123-7577123 17:7673805-7673805
32 BRAF NM_001374258.1(BRAF):c.1922A>C (p.Lys641Thr) SNV Likely pathogenic 44818 rs397507484 7:140453133-140453133 7:140753333-140753333
33 MLH1 NM_000249.4(MLH1):c.1151T>A (p.Val384Asp) SNV Likely pathogenic 41632 rs63750447 3:37067240-37067240 3:37025749-37025749
34 TP53 NM_000546.5(TP53):c.743G>C (p.Arg248Pro) SNV Likely pathogenic 237954 rs11540652 17:7577538-7577538 17:7674220-7674220
35 TP53 NM_000546.5(TP53):c.332T>G (p.Leu111Arg) SNV Likely pathogenic 376631 rs1057519997 17:7579355-7579355 17:7676037-7676037
36 NRAS NM_002524.5(NRAS):c.34G>C (p.Gly12Arg) SNV Likely pathogenic 40469 rs121913250 1:115258748-115258748 1:114716127-114716127
37 TP53 NM_000546.5(TP53):c.526T>A (p.Cys176Ser) SNV Likely pathogenic 376570 rs967461896 17:7578404-7578404 17:7675086-7675086
38 TP53 NM_000546.5(TP53):c.746G>T (p.Arg249Met) SNV Likely pathogenic 376653 rs587782329 17:7577535-7577535 17:7674217-7674217
39 TP53 NM_000546.5(TP53):c.658T>A (p.Tyr220Asn) SNV Likely pathogenic 376688 rs530941076 17:7578191-7578191 17:7674873-7674873
40 TP53 NM_000546.5(TP53):c.645T>G (p.Ser215Arg) SNV Likely pathogenic 376661 rs1057520001 17:7578204-7578204 17:7674886-7674886
41 PIK3CA NM_006218.4(PIK3CA):c.3127A>T (p.Met1043Leu) SNV Likely pathogenic 376487 rs1057519936 3:178952072-178952072 3:179234284-179234284
42 RAF1 NM_001354689.3(RAF1):c.770C>G (p.Ser257Trp) SNV Likely pathogenic 376514 rs80338796 3:12645699-12645699 3:12604200-12604200
43 NRAS NM_002524.5(NRAS):c.182A>C (p.Gln61Pro) SNV Likely pathogenic 280409 rs11554290 1:115256529-115256529 1:114713908-114713908
44 CDKN2A NM_058195.3(CDKN2A):c.194-3470G>T SNV Likely pathogenic 376384 rs1057519882 9:21974677-21974677 9:21974678-21974678
45 ERBB2 NM_004448.3(ERBB2):c.2326G>A (p.Gly776Ser) SNV Likely pathogenic 13879 rs28933369 17:37880997-37880997 17:39724744-39724744
46 SMAD4 NM_005359.6(SMAD4):c.1156G>T (p.Gly386Cys) SNV Likely pathogenic 376539 rs1057519962 18:48593405-48593405 18:51067035-51067035
47 TP53 NM_000546.5(TP53):c.706T>G (p.Tyr236Asp) SNV Likely pathogenic 142183 rs587782289 17:7577575-7577575 17:7674257-7674257
48 MAP2K1 NM_002755.3(MAP2K1):c.157T>G (p.Phe53Val) SNV Likely pathogenic 376446 rs1057519728 15:66727441-66727441 15:66435103-66435103
49 TP53 NM_000546.5(TP53):c.701A>C (p.Tyr234Ser) SNV Likely pathogenic 376690 rs587780073 17:7577580-7577580 17:7674262-7674262
50 TP53 NM_000546.6(TP53):c.523C>T (p.Arg175Cys) SNV Likely pathogenic 245851 rs138729528 17:7578407-7578407 17:7675089-7675089

Cosmic variations for Gastric Adenocarcinoma:

9 (show top 50) (show all 45057)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM94780361 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.1159G>A p.A387T 18:25226759-25226759 12
2 COSM131486960 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.1159G>A p.A387T 18:25226759-25226759 12
3 COSM140706619 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.499G>A p.A167T 18:25226759-25226759 12
4 COSM94777296 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.2285G>A p.R762H 18:25225633-25225633 12
5 COSM131495211 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.443G>A p.C148Y 18:25227475-25227475 12
6 COSM140704933 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.1625G>A p.R542H 18:25225633-25225633 12
7 COSM94795709 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.3434T>G p.V1145G 18:25224484-25224484 12
8 COSM94788727 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.443G>A p.C148Y 18:25227475-25227475 12
9 COSM140712668 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.-218G>A p.? 18:25227475-25227475 12
10 COSM131483683 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.2285G>A p.R762H 18:25225633-25225633 12
11 COSM131502188 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.3434T>G p.V1145G 18:25224484-25224484 12
12 COSM140717636 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.2774T>G p.V925G 18:25224484-25224484 12
13 COSM89892679 ZNF384 stomach,NS,carcinoma,adenocarcinoma c.1136G>A p.R379Q 12:6669044-6669044 12
14 COSM99686061 ZNF384 stomach,NS,carcinoma,adenocarcinoma c.1319G>A p.R440Q 12:6669044-6669044 12
15 COSM96892872 ZNF384 stomach,NS,carcinoma,adenocarcinoma c.1319G>A p.R440Q 12:6669044-6669044 12
16 COSM92495186 ZNF384 stomach,NS,carcinoma,adenocarcinoma c.971G>A p.R324Q 12:6669044-6669044 12
17 COSM90523509 ZNF341 stomach,NS,carcinoma,adenocarcinoma c.2512G>A p.A838T 20:33791485-33791485 12
18 COSM98293254 ZNF341 stomach,NS,carcinoma,adenocarcinoma c.2533G>A p.A845T 20:33791485-33791485 12
19 COSM84509305 ZNF276 stomach,NS,carcinoma,adenocarcinoma c.*677T>G p.? 16:89738923-89738923 12
20 COSM102042239 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.5456G>T p.R1819L 16:72794484-72794484 12
21 COSM149288723 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1081G>A p.G361R 16:72959065-72959065 12
22 COSM149261321 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1858C>T p.H620Y 16:72958288-72958288 12
23 COSM102020152 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.-23-7323C>T p.? 16:72958288-72958288 12
24 COSM87271088 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1858C>T p.H620Y 16:72958288-72958288 12
25 COSM87290698 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.795C>A p.D265E 16:72959351-72959351 12
26 COSM87291716 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.4553G>T p.G1518V 16:72798129-72798129 12
27 COSM149332052 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.5929G>C p.G1977R 16:72796753-72796753 12
28 COSM87280547 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1081G>A p.G361R 16:72959065-72959065 12
29 COSM102040971 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.-23-8386C>A p.? 16:72959351-72959351 12
30 COSM87291652 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.8198G>T p.R2733L 16:72794484-72794484 12
31 COSM87296752 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.5929G>C p.G1977R 16:72796753-72796753 12
32 COSM149318848 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.4553G>T p.G1518V 16:72798129-72798129 12
33 COSM149318790 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.8198G>T p.R2733L 16:72794484-72794484 12
34 COSM102042308 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1811G>T p.G604V 16:72798129-72798129 12
35 COSM149315912 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.795C>A p.D265E 16:72959351-72959351 12
36 COSM102030210 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.-23-8100G>A p.? 16:72959065-72959065 12
37 COSM102048038 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.3187G>C p.G1063R 16:72796753-72796753 12
38 COSM89893344 YES1 stomach,NS,carcinoma,adenocarcinoma c.350G>A p.R117K 18:751726-751726 12
39 COSM136835352 YES1 stomach,NS,carcinoma,adenocarcinoma c.365G>A p.R122K 18:751726-751726 12
40 COSM152021882 YES1 stomach,NS,carcinoma,adenocarcinoma c.350G>A p.R117K 18:751726-751726 12
41 COSM143039512 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 12
42 COSM145026456 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 12
43 COSM85235472 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 12
44 COSM128450026 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 12
45 COSM126971185 YAP1 stomach,NS,carcinoma,adenocarcinoma c.-179C>G p.? 11:102114178-102114178 12
46 COSM133271379 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 12
47 COSM127996054 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 12
48 COSM90945716 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 12
49 COSM97252932 XRCC2 stomach,NS,carcinoma,adenocarcinoma c.140A>G p.H47R 7:152649345-152649345 12
50 COSM101975785 XPO1 stomach,NS,carcinoma,adenocarcinoma c.479G>A p.S160N 2:61499824-61499824 12

Copy number variations for Gastric Adenocarcinoma from CNVD:

7 (show all 39)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 14963 1 111600000 115900000 Gain PIFO Gastric adenocarcinoma
2 14964 1 111600000 115900000 Gain CHIA Gastric adenocarcinoma
3 14966 1 111600000 115900000 Gain OVGP1 Gastric adenocarcinoma
4 33992 1 51300000 56200000 Loss LRP8 Gastric adenocarcinoma
5 38160 10 1 3000000 Gain DIP2C Gastric adenocarcinoma
6 48224 10 99400000 102000000 Gain CHUK Gastric adenocarcinoma
7 48225 10 99400000 102000000 Gain CWF19L1 Gastric adenocarcinoma
8 48226 10 99400000 102000000 Gain ERLIN1 Gastric adenocarcinoma
9 48323 11 1 21600000 Gain DENND2B Gastric adenocarcinoma
10 66124 12 25358179 25403863 Amplification KRAS Gastric adenocarcinoma
11 80193 13 86500000 88800000 Loss SLITRK5 Gastric adenocarcinoma
12 81497 14 103000000 106368585 Loss IGHV3-22 Gastric adenocarcinoma
13 92520 15 41400000 42700000 Loss CAPN3 Gastric adenocarcinoma
14 92521 15 41400000 42700000 Loss GANC Gastric adenocarcinoma
15 93577 15 55800000 57100000 Gain LDHAL6B Gastric adenocarcinoma
16 93578 15 55800000 57100000 Gain MYO1E Gastric adenocarcinoma
17 97919 16 14700000 16700000 Gain PKD1P3 Gastric adenocarcinoma
18 112023 17 3773917 3814485 Loss ATP2A3 Gastric adenocarcinoma
19 112078 17 37844392 37884914 Amplification Gastric adenocarcinoma
20 112310 17 3854487 3993002 Loss ZZEF1 Gastric adenocarcinoma
21 130603 19 50000000 53800000 Gain Gastric adenocarcinoma
22 135991 12 128122223 128954165 Gain TMEM132D Gastric adenocarcinoma
23 159208 21 41400000 46944323 Loss HSF2BP Gastric adenocarcinoma
24 159209 21 41400000 46944323 Loss RRP1B Gastric adenocarcinoma
25 166094 3 1 3500000 Loss CNTN6 Gastric adenocarcinoma
26 169827 3 14700000 23800000 Loss UBE2E1 Gastric adenocarcinoma
27 182313 4 139500000 141700000 Loss MAML3 Gastric adenocarcinoma
28 184256 4 172200000 176600000 Loss Gastric adenocarcinoma
29 195591 5 152100000 155600000 Loss TIMD4 Gastric adenocarcinoma
30 201331 5 68400000 73300000 Gain FCHO2 Gastric adenocarcinoma
31 221297 7 142800000 147500000 Loss CNTNAP2 Gastric adenocarcinoma
32 233707 8 12700000 19100000 Gain Gastric adenocarcinoma
33 236938 8 19100000 23400000 Loss INTS10 Gastric adenocarcinoma
34 237477 8 23400000 27400000 Loss CDCA2 Gastric adenocarcinoma
35 237478 8 23400000 27400000 Loss DOCK5 Gastric adenocarcinoma
36 237479 8 23400000 27400000 Loss GNRH1 Gastric adenocarcinoma
37 237480 8 23400000 27400000 Loss KCTD9 Gastric adenocarcinoma
38 237883 8 27400000 29700000 Loss EXTL3 Gastric adenocarcinoma
39 262032 X 29400000 31500000 Gain XK Gastric adenocarcinoma

Expression for Gastric Adenocarcinoma

Search GEO for disease gene expression data for Gastric Adenocarcinoma.

Pathways for Gastric Adenocarcinoma

Pathways related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 125)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 TP53 SMAD4 PTEN KRAS HRAS FGFR2
2
Show member pathways
13.63 TP53 SMAD4 PIK3CA KRAS HRAS FGFR2
3
Show member pathways
13.6 SMAD4 PIK3CA KRAS HRAS FGFR2 ERBB2
4
Show member pathways
13.56 TP53 PTEN PIK3CA KRAS HRAS FGFR2
5
Show member pathways
13.45 TP53 PIK3CA KRAS HRAS FGFR2 ERBB2
6
Show member pathways
13.41 SMAD4 PTEN KRAS HRAS FGFR2 ERBB2
7
Show member pathways
13.2 TP53 PTEN PIK3CA FGFR2 ERBB2 AKT1
8
Show member pathways
13.18 TP53 PTEN PIK3CA KRAS HRAS CTNNB1
9
Show member pathways
13.17 TP53 SMAD4 PIK3CA KRAS HRAS CTNNB1
10
Show member pathways
13.16 TP53 PTEN KRAS HRAS FGFR2 AKT1
11
Show member pathways
13.12 TP53 PTEN PIK3CA KRAS HRAS FGFR2
12
Show member pathways
13.05 TP53 PIK3CA KRAS HRAS CTNNB1 CDKN2A
13
Show member pathways
13.01 PTEN PIK3CA KRAS HRAS ERBB2 AKT1
14
Show member pathways
13.01 PTEN PIK3CA KRAS HRAS ERBB2 CTNNB1
15
Show member pathways
12.98 PTEN PIK3CA KRAS HRAS FGFR2 ERBB2
16 12.88 TP53 KRAS HRAS FGFR2 ERBB2 AKT1
17
Show member pathways
12.87 PTEN PIK3CA KRAS HRAS AKT1
18
Show member pathways
12.86 TP53 PTEN PIK3CA KRAS HRAS FGFR2
19
Show member pathways
12.85 PIK3CA KRAS HRAS FGFR2 CTNNB1 AKT1
20
Show member pathways
12.85 TP53 PTEN PIK3CA KRAS HRAS ERBB2
21
Show member pathways
12.85 TP53 SMAD4 PTEN PIK3CA MLH1 KRAS
22
Show member pathways
12.82 TP53 PIK3CA KRAS HRAS CDKN2A AKT1
23 12.76 TP53 SMAD4 PTEN PIK3CA MLH1 KRAS
24
Show member pathways
12.75 TP53 PTEN PIK3CA KRAS HRAS FGFR2
25
Show member pathways
12.74 PIK3CA KRAS HRAS CTNNB1 AKT1
26
Show member pathways
12.74 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
27
Show member pathways
12.73 TP53 PTEN PIK3CA KRAS HRAS FGFR2
28
Show member pathways
12.71 PTEN PIK3CA KRAS HRAS AKT1
29
Show member pathways
12.69 PTEN PIK3CA KRAS HRAS AKT1
30 12.69 TP53 PTEN PIK3CA KRAS HRAS ERBB2
31
Show member pathways
12.63 TP53 PTEN PIK3CA KRAS HRAS FGFR2
32
Show member pathways
12.61 PTEN PIK3CA KRAS HRAS ERBB2 AKT1
33
Show member pathways
12.57 PTEN PIK3CA KRAS HRAS AKT1
34
Show member pathways
12.55 TP53 PIK3CA KRAS HRAS FGFR2 ERBB2
35
Show member pathways
12.53 PTEN PIK3CA KRAS HRAS AKT1
36
Show member pathways
12.52 PIK3CA KRAS HRAS FGFR2 ERBB2 CTNNB1
37
Show member pathways
12.52 PIK3CA KRAS HRAS CTNNB1 AKT1
38
Show member pathways
12.52 PIK3CA KRAS HRAS FGFR2 AKT1
39
Show member pathways
12.52 TP53 SMAD4 PTEN PIK3CA KRAS HRAS
40
Show member pathways
12.51 TP53 PTEN PIK3CA HRAS AKT1
41
Show member pathways
12.49 PIK3CA KRAS HRAS AKT1
42
Show member pathways
12.49 PIK3CA KRAS HRAS ERBB2 CTNNB1 AKT1
43
Show member pathways
12.46 TP53 PTEN PIK3CA HRAS ERBB2 CTNNB1
44 12.44 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
45
Show member pathways
12.42 PIK3CA HRAS CTNNB1 AKT1
46 12.42 TP53 PIK3CA KRAS HRAS CDKN2A
47
Show member pathways
12.41 PIK3CA HRAS ERBB2 AKT1
48
Show member pathways
12.41 PIK3CA KRAS HRAS ERBB2 AKT1
49
Show member pathways
12.4 TP53 PIK3CA HRAS AKT1
50
Show member pathways
12.4 TP53 KRAS HRAS AKT1

GO Terms for Gastric Adenocarcinoma

Biological processes related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.11 TP53 SMAD4 HRAS FGFR2 CTNNB1 CDKN2A
2 apoptotic process GO:0006915 10 TP53 PTEN HRAS FGFR2 CDKN2A AKT1
3 heart development GO:0007507 9.92 TP53 PTEN ERBB2 CTNNB1
4 in utero embryonic development GO:0001701 9.91 TP53 SMAD4 FGFR2 CTNNB1
5 positive regulation of apoptotic process GO:0043065 9.91 TP53 PTEN CTNNB1 CDKN2A AKT1
6 positive regulation of protein phosphorylation GO:0001934 9.88 KRAS HRAS ERBB2 AKT1
7 positive regulation of protein kinase B signaling GO:0051897 9.85 PIK3CA H19 FGFR2 ERBB2
8 negative regulation of cell proliferation GO:0008285 9.8 TP53 SMAD4 PTEN HRAS CTNNB1 CDKN2A
9 cellular response to growth factor stimulus GO:0071363 9.77 ERBB2 CTNNB1 AKT1
10 positive regulation of epithelial cell proliferation GO:0050679 9.75 HRAS FGFR2 ERBB2
11 positive regulation of MAP kinase activity GO:0043406 9.73 KRAS HRAS ERBB2
12 positive regulation of cell proliferation GO:0008284 9.7 PTEN KRAS HRAS FGFR2 ERBB2 CTNNB1
13 positive regulation of MAPK cascade GO:0043410 9.67 HRAS FGFR2 ERBB2 CTNNB1
14 embryonic organ development GO:0048568 9.63 TP53 FGFR2 CTNNB1
15 anoikis GO:0043276 9.62 PIK3CA AKT1
16 negative regulation of cell size GO:0045792 9.61 PTEN AKT1
17 protein kinase B signaling GO:0043491 9.61 PTEN PIK3CA AKT1
18 response to isolation stress GO:0035900 9.59 KRAS HRAS
19 Ras protein signal transduction GO:0007265 9.56 TP53 KRAS HRAS CDKN2A
20 lung-associated mesenchyme development GO:0060484 9.54 FGFR2 CTNNB1
21 negative regulation of immature T cell proliferation in thymus GO:0033088 9.49 ERBB2 CDKN2A
22 cellular response to decreased oxygen levels GO:0036294 9.48 PTEN AKT1
23 mesenchymal cell proliferation involved in lung development GO:0060916 9.4 FGFR2 CTNNB1
24 phosphatidylinositol 3-kinase signaling GO:0014065 9.26 PTEN PIK3CA ERBB2 AKT1
25 positive regulation of gene expression GO:0010628 9.23 TP53 PTEN KRAS HRAS ERBB2 CTNNB1

Molecular functions related to Gastric Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.72 TP53 PTEN CTNNB1 CDKN2A AKT1
2 enzyme binding GO:0019899 9.55 TP53 PTEN MLH1 CTNNB1 AKT1
3 MDM2/MDM4 family protein binding GO:0097371 9.26 TP53 CDKN2A
4 RNA polymerase II transcription factor binding GO:0001085 9.13 TP53 SMAD4 CTNNB1
5 disordered domain specific binding GO:0097718 8.8 TP53 CTNNB1 CDKN2A

Sources for Gastric Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....